PMID- 14752070
OWN - NLM
STAT- MEDLINE
DCOM- 20040224
LR  - 20151119
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 22
IP  - 3
DP  - 2004 Feb 1
TI  - Combination of cytology, fluorescence in situ hybridization for aneuploidy, and 
      reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin 
      B expression improves diagnosis of malignant effusions.
PG  - 474-83
AB  - PURPOSE: The identification of malignant cells in effusions by conventional 
      cytology is hampered by its limited sensitivity. The aim of this study was to 
      improve tumor cell detection in effusions by molecular approaches. MATERIALS AND 
      METHODS: A total of 157 effusions from patients with tumors and 72 effusions from 
      patients without a history or evidence of malignancy were included in this study. 
      All effusion specimens were evaluated in parallel by cytology, fluorescence in 
      situ hybridization (FISH) for aneuploidy, and reverse-transcriptase polymerase 
      chain reaction (RT-PCR) for expression of human mammaglobin (hMAM) and 
      mammaglobin B (hMAM-B). RESULTS: In effusions from patients with tumors, the 
      sensitivities of tumor cell detection by cytology, FISH, and hMAM and hMAM-B 
      detection were 46.2%, 53.3%, 36.4%, and 57.7%, respectively. The corresponding 
      specificities were 94.4%, 97.0%, 87.1%, and 88.6%. Notably, a high percentage of 
      effusions containing malignant cells were in fact transudates, indicating the 
      necessity for molecular diagnostic work-up of transudates collected from patients 
      with tumors. Dependent on the tumor type, the use of appropriate marker 
      combinations improved tumor cell detection in effusions significantly. By 
      combining all four diagnostic tests, a positive test result indicating the 
      presence of malignancy was achieved in 81.1%, with a fairly good specificity of 
      70.1%. CONCLUSION: Molecular techniques are definitely useful to detect 
      malignancy in cytologically negative effusions. Tumor cell detection in effusions 
      can be significantly improved by FISH and PCR techniques applying appropriate 
      molecular markers. This finding should help to improve tumor staging, prognostic 
      assessment, and treatment monitoring.
FAU - Fiegl, Michael
AU  - Fiegl M
AD  - Department of Internal Medicine, Division of Hematology and Oncology, Innsbruck 
      University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. 
      michael.fiegl@uibk.ac.at
FAU - Haun, Margot
AU  - Haun M
FAU - Massoner, Anita
AU  - Massoner A
FAU - Krugmann, Jens
AU  - Krugmann J
FAU - Muller-Holzner, Elisabeth
AU  - Muller-Holzner E
FAU - Hack, Rene
AU  - Hack R
FAU - Hilbe, Wolfgang
AU  - Hilbe W
FAU - Marth, Christian
AU  - Marth C
FAU - Duba, Hans-Christoph
AU  - Duba HC
FAU - Gastl, Gunther
AU  - Gastl G
FAU - Grunewald, Kurt
AU  - Grunewald K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Mammaglobin A)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (SCGB2A2 protein, human)
RN  - 9060-09-7 (Uteroglobin)
SB  - IM
MH  - *Aneuploidy
MH  - Ascitic Fluid/*metabolism
MH  - Biomarkers, Tumor/analysis
MH  - Cytological Techniques
MH  - Epithelial Cells/metabolism
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Mammaglobin A
MH  - Neoplasm Proteins/*genetics
MH  - Neoplasms/*metabolism/pathology
MH  - Pleural Effusion, Malignant/*metabolism
MH  - RNA, Messenger/metabolism
MH  - RNA, Neoplasm
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sensitivity and Specificity
MH  - Uteroglobin/*genetics
EDAT- 2004/01/31 05:00
MHDA- 2004/02/26 05:00
CRDT- 2004/01/31 05:00
PHST- 2004/01/31 05:00 [pubmed]
PHST- 2004/02/26 05:00 [medline]
PHST- 2004/01/31 05:00 [entrez]
AID - JCO.2004.06.063 [pii]
AID - 10.1200/JCO.2004.06.063 [doi]
PST - ppublish
SO  - J Clin Oncol. 2004 Feb 1;22(3):474-83. doi: 10.1200/JCO.2004.06.063.